Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
185 GBX | +4.23% | -3.90% | -39.34% |
May. 22 | Transcript : Faron Pharmaceuticals Oy - Special Call | |
May. 20 | Faron Pharmaceuticals’ Blood Cancer Combo Shows Efficacy in Mid-stage Study | MT |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 134.4 | 136.4 | 169.4 | 202.7 | 241.9 | 156.3 | - | - |
Enterprise Value (EV) 1 | 130.2 | 132.4 | 163 | 206.8 | 247.9 | 186.9 | 114 | 156.3 |
P/E ratio | -10 x | -7.86 x | -7.58 x | -6.52 x | -7.33 x | -7.08 x | -14 x | -7 x |
Yield | - | - | - | - | - | 0.69% | - | - |
Capitalization / Revenue | - | - | - | - | - | 10.9 x | 4 x | 13.2 x |
EV / Revenue | - | - | - | - | - | 13 x | 2.92 x | 13.2 x |
EV / EBITDA | -10.1 x | -8.09 x | -7.84 x | -7.62 x | -8.78 x | -53.9 x | -43.4 x | -4.95 x |
EV / FCF | - | - | - | -8.85 x | -10.4 x | 8.63 x | -3.85 x | -4.36 x |
FCF Yield | - | - | - | -11.3% | -9.65% | 11.6% | -26% | -22.9% |
Price to Book | - | - | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 43,291 | 46,897 | 53,232 | 59,805 | 68,787 | 72,007 | - | - |
Reference price 2 | 3.104 | 2.909 | 3.182 | 3.389 | 3.516 | 2.171 | 2.171 | 2.171 |
Announcement Date | 3/20/20 | 3/25/21 | 3/25/22 | 3/3/23 | 3/13/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | 14.4 | 39.09 | 11.85 |
EBITDA 1 | -12.86 | -16.37 | -20.8 | -27.13 | -28.22 | -3.466 | -2.626 | -31.55 |
EBIT 1 | -13.1 | -16.65 | -21.11 | -27.43 | -28.57 | -3.733 | -3.033 | -32.55 |
Operating Margin | - | - | - | - | - | -25.93% | -7.76% | -274.68% |
Earnings before Tax (EBT) 1 | -13.25 | -16.94 | -21.18 | -28.73 | -30.94 | -5.7 | -4.6 | -34.95 |
Net income 1 | -13.26 | -16.95 | -21.19 | -28.73 | -30.94 | -6.367 | -4.6 | -34.95 |
Net margin | - | - | - | - | - | -44.21% | -11.77% | -294.94% |
EPS 2 | -0.3100 | -0.3700 | -0.4200 | -0.5200 | -0.4800 | -0.3067 | -0.1550 | -0.3100 |
Free Cash Flow 1 | - | - | - | -23.38 | -23.93 | 21.65 | -29.6 | -35.85 |
FCF margin | - | - | - | - | - | 150.35% | -75.72% | -302.53% |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
Dividend per Share 2 | - | - | - | - | - | 0.0150 | - | - |
Announcement Date | 3/20/20 | 3/25/21 | 3/25/22 | 3/3/23 | 3/13/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2019 S2 | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 | 2025 S1 | 2025 S2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA 1 | -6.568 | -7.015 | -9.356 | -10.28 | - | -13.21 | -13.91 | -12.64 | -15.58 | -13.9 | -15.7 | - | - |
EBIT 1 | -6.758 | -7.145 | -9.509 | -10.42 | -10.68 | -13.36 | -14.06 | -12.81 | -15.76 | -14.1 | -15.9 | - | - |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -6.84 | -7.343 | -9.593 | -10.55 | -10.62 | -13.1 | -15.63 | -13.73 | -17.21 | -15.3 | -17.2 | - | - |
Net income 1 | -6.85 | -7.343 | -9.603 | -10.56 | -10.63 | -13.12 | -15.61 | -13.73 | -17.21 | -15.3 | -17.2 | - | - |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | -0.1600 | -0.1600 | -0.2200 | -0.2100 | -0.2100 | -0.2500 | -0.2700 | -0.2200 | -0.2600 | -0.2100 | -0.2100 | - | - |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 3/20/20 | 9/24/20 | 3/25/21 | 8/26/21 | 3/25/22 | 8/25/22 | 3/3/23 | 8/29/23 | 3/13/24 | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | 4.11 | 6.02 | 30.6 | - | - |
Net Cash position 1 | 4.24 | 3.99 | 6.42 | - | - | - | 42.3 | - |
Leverage (Debt/EBITDA) | - | - | - | -0.1516 x | -0.2134 x | -8.829 x | - | - |
Free Cash Flow 1 | - | - | - | -23.4 | -23.9 | 21.7 | -29.6 | -35.9 |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - | - |
Cash Flow per Share 2 | -0.3200 | - | -0.4400 | -0.4200 | - | -0 | 0 | - |
Capex 1 | - | 0.01 | 0.01 | 0.39 | 0.12 | 0.1 | 0.47 | 1.7 |
Capex / Sales | - | - | - | - | - | 0.69% | 1.19% | 14.35% |
Announcement Date | 3/20/20 | 3/25/21 | 3/25/22 | 3/3/23 | 3/13/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-39.34% | 169M | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B | |
+77.64% | 8.87B |
- Stock Market
- Equities
- FARN Stock
- Financials Faron Pharmaceuticals Oy